Ticker
ADXN

Price
1.25
Stock movement up
+0.09 (7.76%)
Company name
Addex Therapeutics Ltd
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
24.03M
Ent værdi
17.90M
Pris/omsætning
19.58
Pris/bog
3.02
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-78.19%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2023-02-02

UDBYTTE

ADXN betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning19.58
Pris til egenkapital3.02
EV i forhold til salg14.58

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier19.22M
EPS (TTM)-2.71
FCF pr. aktie (TTM)-2.05

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)1.23M
Bruttofortjeneste (TTM)0.00
Driftsindkomst (TTM)-21.30M
Nettoindkomst (TTM)-21.58M
EPS (TTM)-2.71
EPS (1 år frem)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-1735.01%
Fortjenstmargin (TTM)-1757.77%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter10.42M
Nettotilgodehavender457.04K
Omsætningsaktiver i alt11.70M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver12.24M
Kreditor2.99M
Kortfristet/nuværende langsigtet gæld447.11K
Summen af kortfristede forpligtelser4.13M
Sum gæld4.29M
Aktionærernes egenkapital7.95M
Materielle nettoaktiver7.95M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-16.31M
Investeringsudgifter (TTM)26.23K
Fri pengestrøm (TTM)-16.34M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-271.34%
Afkast af aktiver-176.26%
Afkast af investeret kapital-261.93%
Kontant afkast af investeret kapital-198.31%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning1.20
Daglig høj1.35
Daglig lav1.20
Daglig volumen494K
Højeste gennem alle tider24.19
1 års analytiker estimat-
Beta1.52
EPS (TTM)-2.71
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation2 May 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADXNS&P500
Nuværende prisfald fra top notering-94.83%-12.75%
Højeste prisfald-97.71%-56.47%
Højeste efterår dato22 Dec 20229 Mar 2009
Gennemsnitlig fald fra toppen-66.33%-11.49%
Gennemsnitlig tid til nyt højdepunkt232 days13 days
Maks. tid til nyt højdepunkt530 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ADXN (Addex Therapeutics Ltd) company logo
Markedsværdi
24.03M
Markedsværdi kategori
Small-cap
Beskrivelse
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Personale
26
Investor relationer
-
SEC-indsendelser
Adm. direktør
Timothy Dyer
Land
USA
By
Geneva
Aktietype
American depositary share
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modul...
19. januar 2023
Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, D...
8. december 2022
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Gen...
11. november 2022
Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
3. november 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modula...
3. november 2022
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modula...
1. november 2022
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, anno...
20. september 2022
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in ...
18. august 2022
Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 15, ...
15. august 2022
Geneva, Switzerland, August 12, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...
12. august 2022
Næste side